Cetuximab plus chemo boosts surgery in advanced colon ca

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 18 No 12
Volume 18
Issue 12

Adding cetuximab (Erbitux) to neoadjuvant chemotherapy shrank tumors enough to increase the success of curative surgery in colon cancer patients with inoperable metastatic liver lesions, according to the CELIM trial conducted in Germany and Austria.

Adding cetuximab (Erbitux) to neoadjuvant chemotherapy shrank tumors enough to increase the success of curative surgery in colon cancer patients with inoperable metastatic liver lesions, according to the CELIM trial conducted in Germany and Austria.

Patients were randomized to cetuximab treatment with FOLFOX6 or with FOLFIRI. Treatment with cetuximab resulted in high tumor response rates and a 28% increase in the proportion of tumors that were amenable to surgery. Ultimately, surgery was achieved in 34% of the patients. Because of cetuximab treatment, 60% of tumors were deemed resectable vs 32% at the start of the study (Lancet Oncology online, November 24, 2009).

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
2 experts in this video
2 experts in this video
Extravasation with beta emitters may elicit more drastic adverse effects due to their higher radiation dose.
Increasing the use of patient-reported outcomes may ensure that practitioners can fully ascertain the impact of treatment for rare lymphomas.
Photographic and written documentation can help providers recognize inflammatory breast cancer symptoms across diverse populations.
The use of guideline-concordant care in breast cancer appears to be more common in White populations than Black populations.
2 experts are featured in this series.
Related Content